Skip to main content
GENESIS IBRC INDIA LIMITED logo

GENESIS IBRC INDIA LIMITED — Investor Relations & Filings

Ticker · 514336 ISIN · INE194N01016 BSE.NS Manufacturing
Open in API
Filings indexed 311 across all filing types
Latest filing 2026-05-30 Audit Report / Informat…
Country IN India
Listing BSE.NS 514336

About GENESIS IBRC INDIA LIMITED

https://genesisiil.com/

Genesis IBRC India Limited is a biotechnology-driven enterprise focused on the research, development, and commercialization of advanced biological solutions. The company specializes in the production of high-quality probiotics and industrial enzymes tailored for diverse applications. Its product portfolio serves critical sectors including aquaculture, poultry, animal husbandry, and human nutrition, providing microbial formulations designed to enhance growth, immunity, and overall health. In the industrial segment, the company develops enzymatic solutions for the textile, leather, and paper processing sectors to improve efficiency and environmental sustainability. Genesis IBRC emphasizes innovation through its dedicated research facilities, focusing on strain selection and fermentation technology to deliver standardized and effective biochemical products. The company aims to provide science-based alternatives to traditional chemical processes across global markets.

Recent filings

Filing Released Lang Actions
Annual Compliance Audit Report for the financial year ended March 31, 2026
Audit Report / Information Classification · 95% confidence The document is a Secretarial Compliance Audit Report issued by a practicing company secretary under Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It provides a certification of compliance with various SEBI and Companies Act provisions and details deviations and actions taken. This is not an Annual Report, Management Discussion & Analysis, or mere publication notice—it is a standalone attestation/audit report. Thus it best fits the “Audit Report / Information” category (Code: AR). FY 2026
2026-05-30 English
Statement of deviation for the quarter and financial year ended March 31, 2026
Regulatory Filings Classification · 92% confidence The document is a “Statement on Deviation or Variation for Proceeds of … Preferential Issue” filed under SEBI Listing Regulations, showing quarterly compliance on the use of funds raised. It is a statutory regulatory disclosure rather than a management report, financial statement, or announcement of a new issue. It therefore falls under the general Regulatory Filings category (RNS).
2026-05-29 English
Results for the quarter and financial year ended March 31, 2026
Regulatory Filings Classification · 78% confidence The document is an official SEBI LODR Regulation 30 & 33 filing notifying the stock exchange of the Board meeting outcome (May 29, 2026), approval of audited financial results for Q4 and year ended March 31, 2026, declaration of unmodified opinion, and attachments of the Audit Report and financial result tables. It is not a standalone full annual report (10-K), nor merely an earnings release, nor a pure interim report. It is a regulatory disclosure filing to the exchange, best classified under Regulatory Filings (RNS).
2026-05-29 English
Outcome of board meeting held on May 29, 2026.
Interim / Quarterly Report Classification · 90% confidence The document is a formal board meeting outcome under SEBI LODR Regulations 30 and 33, announcing and enclosing the audited financial results and the independent auditor’s report for the quarter and full year ended March 31, 2026. It includes actual financial statements (income, expenses, profit/loss, comprehensive income) and the auditors’ opinion. This is more than a headline earnings release but is not a full narrative annual report; it is a substantive financial report for a specific period. Under our taxonomy, this aligns with an Interim/Quarterly Report (IR). FY 2026
2026-05-29 English
CCME Global Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Intimation of the board meeting ....
Regulatory Filings Classification · 58% confidence The document is an official intimation to the stock exchange under SEBI Listing Regulations notifying a scheduled board meeting to consider and approve audited financial results. It does not itself contain financial statements, nor does it announce a change in board composition; it simply provides a regulatory notice. This does not fit Annual Report (10-K), Interim Report (IR), Earnings Release (ER) or specific board-change filings (MANG), nor is it the actual report publication (RPA). It is a general compliance announcement, so it falls under the fallback category for miscellaneous regulatory filings (RNS).
2026-05-22 English
Intimation about receipt of listing approval for 32250000 equity shares allotted on March 26, 2026
Capital/Financing Update Classification · 95% confidence The document is a formal letter addressed to the stock exchange (BSE Limited) informing about the approval received for listing of equity shares issued on a preferential basis. It references SEBI Listing Regulations and provides details about the shares allotted. The document is short (1882 characters) and serves as an announcement of a capital market event related to share issuance and listing approval. It does not contain financial statements or detailed financial data, nor is it a report or presentation. Therefore, it fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2026-04-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.